Moviprep Orange

Polyethylene glycol (PEG) with ascorbic acid, the active ingredient in Moviprep Orange, is an osmotic laxative presented as an oral powder for solution for oral administration. It facilitates rapid bowel evacuation, providing effective colon cleansing for adults undergoing colonoscopy, sigmoidoscopy, or radiologic colon examinations. The preparation is designed to be mixed with water and consumed according to the prescribing clinician’s instructions, ensuring adequate hydration and electrolyte balance during the cleansing process. GNH USA supplies Moviprep Orange as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moviprep Orange, an osmotic laxative used for bowel cleansing, is indicated for the following procedures: - Colonoscopy: thorough cleansing of the entire colon, reducing residual stool and improving mucosal visualization during the endoscopic examination. - Sigmoidoscopy: effective evacuation of the distal colon and rectum, providing a clear field for flexible sigmoidoscopic assessment. - Radiologic colon examinations (e.g., CT colonography): preparation of the bowel to minimize fecal material, enhancing image contrast and diagnostic accuracy. - Capsule endoscopy: clears the gastrointestinal tract to allow uninterrupted capsule transit and optimal image capture.

Moviprep Orange may cause gastrointestinal and systemic reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Abdominal cramping: intermittent discomfort or pain in the abdomen. - Bloating: sensation of fullness or gas accumulation. - Diarrhea: loose, watery stools occurring during the cleansing phase. - Electrolyte imbalance: mild changes in sodium or potassium levels. - Flatulence: increased gas production leading to passing of wind.

Serious or Rare Side Effects: - Severe dehydration: marked loss of body fluids requiring medical attention. - Acute kidney injury: sudden decline in renal function, especially in at‑risk patients. - Severe electrolyte disturbances: significant hyponatremia or hyperkalemia. - Allergic reaction: rash, itching, swelling, or difficulty breathing.

Before prescribing Moviprep Orange, clinicians should consider several precautionary measures to ensure patient safety. - Assess renal function: evaluate kidney performance, especially in patients with chronic kidney disease. - Review electrolyte status: check baseline sodium and potassium levels prior to use. - Ensure adequate hydration: advise patients to drink sufficient clear fluids during preparation. - Contraindicate in bowel obstruction: avoid use in patients with known or suspected intestinal blockage. - Avoid in severe dehydration: do not administer to patients already dehydrated without correction. - Store at ambient temperature: keep the powder below 25°C in the original container, protected from moisture.

Moviprep Orange can influence the pharmacokinetics of several drugs; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Lithium: increased absorption may precipitate toxicity. - Digoxin: altered serum levels can lead to cardiac effects.

Moderate Interactions (Monitor Closely): - Diuretics: combined effect may exacerbate electrolyte disturbances. - ACE inhibitors or ARBs: potential for additive hypotensive or renal effects. - Oral antibiotics: reduced absorption may diminish therapeutic efficacy.